What are Pelthos Therapeutics Inc.'s total assets?

Pelthos Therapeutics Inc. (PTHS) holds $145.4M in total assets, up 15854.9% year over year.

How much debt does Pelthos Therapeutics Inc. have?

Pelthos Therapeutics Inc. carries $29.6M in total debt against $35.1M of shareholders' equity, a debt-to-equity ratio of 0.84.

How much cash does Pelthos Therapeutics Inc. have?

Pelthos Therapeutics Inc. holds $32.0M in cash and equivalents.

Can Pelthos Therapeutics Inc. cover its short-term obligations?

Its current ratio is 2.79 — current assets exceed current liabilities.

Where does Pelthos Therapeutics Inc.'s balance sheet data come from?

Every line is extracted from Pelthos Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Pelthos Therapeutics Inc. PTHS Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Cash and cash equivalents	$31.98M+24,250%	$17.97M+3,404%	$14.2M+1,032%	$59.17K-97.5%	$131.32K-96.5%
Restricted cash	$250K—	$50K—	$50K—	——	$0—
Accounts receivable, net	$11.7M—	$8.86M—	$7.99M—	——	$0—
Inventories	$23.42M—	$23.57M—	$24.1M—	——	$0—
Raw materials	$678K—	$436K—	$605K—	——	——
Work in process	$14.04M—	$16.56M—	$17.03M—	——	——
Finished goods	$8.7M—	$6.58M—	$6.46M—	——	——
Prepaid expenses and other current assets	$2.46M+14,939%	$2.96M+245%	$3.42M+3,520%	$12.34K-92.2%	$16.34K-92.6%
Total current assets	$69.8M+7,561%	$53.41M+3,801%	$49.76M+2,225%	$822.85K-68.4%	$911.18K-77.4%
Property and equipment, net	$9.31M—	$9.59M—	$10.17M—	——	——
Accumulated depreciation	$1.4M—	$932K—	$389K—	——	——
Operating lease right-of-use assets	8.4%—	325,000,000%—	335,200,000%—	——	——
Goodwill	$24.68M—	$24.68M—	$30.63M—	——	——
Intangible assets, net	$38.44M—	$39.47M—	$32.52M—	——	——
Total assets	$145.38M+15,855%	$130.4M+9,425%	$126.43M+5,808%	$822.85K-68.4%	$911.18K-77.4%
Accounts payable	$6.15M+136%	$2.99M+57.4%	$5.67M+343%	$4.99M+497%	$2.6M+8.1%
Accrued expenses	$1.93M—	$3.48M—	$5.56M+1,805,744%	$23.64K-93.5%	——
Deferred revenue	$978K—	$966K—	$1.52M—	——	——
Operating lease liabilities, current	$640K—	$635K—	$631K—	——	——
Contract liabilities	$1.03M—	$1.28M—	——	——	——
Accrued interest	$0—	$234K—	——	——	——
Claims and insurance accruals	$0—	$265K—	——	——	——
Total current liabilities	$25M+390%	$25.99M+537%	$24.77M+594%	$7.32M+163%	$5.11M+76.0%
Long-term debt	$26.36M—	$0—	——	——	——
Operating lease liabilities, non-current	$2.65M—	$2.75M—	$1.58M—	——	——
Operating Lease Liabilities (Total)	$3.29M—	$3.39M—	$2.85M—	——	——
Other non-current liabilities	$31.96M—	$30.05M—	$26.18M—	——	——
Total liabilities	$110.28M+2,059%	$91.52M+2,141%	$68.18M+1,811%	$7.32M+163%	$5.11M+76.0%
Common stock	200M+32,206,019%	200M—	200M0.0%	200M0.0%	621-100.0%
Additional paid-in capital	$106.95M+456%	$103.68M+453%	$101.38M+460%	$20.4M+15.4%	$19.25M+11.8%
Retained earnings	-$75.03M-220%	-$64.79M-202%	-$43.13M-121%	-$26.89M-50.6%	-$23.44M-45.8%
Accumulated other comprehensive income (loss)	$3.19M—	$0—	——	——	——
Total stockholders' equity	$35.1M+937%	$38.88M+1,533%	$58.25M+4,179%	-$6.49M-3,429%	-$4.2M-471%
Total liabilities and stockholders' equity	$145.38M+15,855%	$130.4M+9,425%	$126.43M+5,808%	$822.85K-68.4%	$911.18K-77.4%
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)	$32.23M+24,500%	$18.02M+3,413%	——	——	$131K—
Finished goods	$8.7M—	$6.58M—	——	——	——
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	$3.82M—	——	——	——	——
Finite Lived Intangible Assets - Gross	$41.03M—	——	——	——	——
Goodwill and Intangible Assets, Net	$63.12M—	$64.15M—	$63.15M—	——	——
Net Investment in Lease	$3.15M—	$3.25M—	$3.35M—	——	——
Intangible assets — net	$38.44M—	$39.47M—	——	——	——
Goodwill and intangible assets, net	$63.12M—	$64.15M—	$63.15M—	——	——
Operating lease right-of-use assets	$3.15M—	$3.25M—	$3.35M—	——	——
Property, plant and equipment at cost	$10.71M—	$10.52M—	$10.56M—	——	——
Operating Lease Right-of-Use Assets in Other Assets	$3.15M—	$3.25M—	$3.35M—	——	——
Accrued Manufacturing Costs	$1.93M—	$3.48M—	——	——	——
Accrued Progress Collections and Price Adjustments	$1.03M—	$1.28M—	——	——	——
Accrued Royalties (Current)	$8.17M—	$7.82M—	$6.25M—	——	——
Other Commercial Liabilities	$12.84M—	$15.36M—	$11.89M+3,860,290%	$23.64K-93.5%	——
Accrued Liabilities, Current	$12.84M—	$15.36M—	$11.89M+3,860,290%	$23.64K-93.5%	——
Compensation and benefits	$1.93M—	$3.48M—	——	——	——
Other accrued liabilities	$3.4M—	$3.84M—	$5.56M—	——	——
Customer Deposits	$164K—	$80K—	——	——	——
Lease Liability Payments - 2020 (Remaining Three Months)	$499K—	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	$705K—	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	$748K—	——	——	——	——
Lease Liability Payments - Due Year Two	$705K—	——	——	——	——
Lease Liability Payments - Due Year Three	$726K—	——	——	——	——
Lease Liability Payments - Due Year Four	$748K—	——	$726K—	——	——
Lease Liability Payments - Remainder of Fiscal Year	$685K—	——	——	——	——
Operating Lease Liability Payments Due	$4.2M—	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	$907K—	——	$1.05M—	——	——
Contract Liabilities, Non-Current	$1.03M—	$1.28M—	——	——	——
Convertible Debt (Non-Current)	$23.28M—	$31.44M—	——	——	——
Operating Lease Liability Payments - 2026 (Lessee)	$726K—	——	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	$726K—	——	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	$748K—	——	——	——	——
Deferred revenue, net of current portion	$1.03M—	$1.28M—	——	——	——
Total debt	$29.65M—	$3.39M—	$2.85M—	——	——
Common Stock Par Value Per Share	$0.00—	$0.000.0%	$0.000.0%	$0.000.0%	——
Common Stock Shares Issued	3.4M—	3.2M+430%	3.1M-46.9%	673.3K-88.4%	——
Common Stock Shares Outstanding	$11M+9,811%	$0—	——	——	$111K—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$0-100%	$0—	——	$67-88.5%	$621+7.4%
Number of Exercisable Options	187.4K+341%	——	133.4K+539%	50.9K+337%	42.5K-66.7%
Number of Vested and Expected to Vest Options	$11M+9,811%	——	——	——	$111K—
Share-Based Payment Award Options Outstanding - Number	1.5M+1,668%	1.5M+1,631%	1.5M+1,764%	94.9K+15.7%	87K-55.9%
Share Price	$21.01—	$31.00—	——	——	——
Shares Reserved for Future Issuance Under Stock Plans	354.5K—	——	——	2.4M+5,300%	——
Weighted Average Exercise Price of Outstanding Options	$16.17-72.3%	$15.96-72.7%	$15.76-74.4%	$54.73-11.1%	$58.48+158%
Weighted Average Exercise Price of Vested and Expected to Vest Options	$16.17-72.3%	——	——	——	$58.48—
Cumulative Cost Basis	$10.71M—	$10.52M—	$10.56M—	——	——
Accrued gross-to-net adjustments	$1.75M—	$1.78M—	——	——	——
Licensing Arrangements	$8.17M—	$7.82M—	——	——	——
Contingent liabilities	$1M—	$2.2M—	——	——	——
Cash and cash equivalents, end of period	$32.23M+24,500%	$18.02M+3,413%	——	——	$131K—
Commercial data platforms	$117K—	$364K—	——	——	——
Common stock, capital shares reserved for future issuance	$354.5K—	——	——	$2.4M+5,300%	——
Common stock, par value (in dollars per share)	$0—	$00.0%	$00.0%	$00.0%	——
Common stock, shares authorized (in shares)	$200M—	$200M0.0%	$200M0.0%	$200M0.0%	——
Common stock, shares issued (in shares)	$3.37M—	$3.23M+430%	$3.09M-46.9%	$673.32K-88.4%	——
Common Stock, Shares, Outstanding	$3.37M—	$3.23M+430%	$3.09M-46.9%	$673.32K-88.4%	——
Convertible debentures	$23.28M—	$31.44M—	——	——	——
Debt Instrument Fee Amount	$663K—	——	——	——	——
Third party fees	$1.81M—	——	——	——	——
Debt Instruments And Warrants, Fair Value Allocation, Percent	100%—	——	——	——	——
Debt Instruments And Warrants, Fair Value Allocation, Amount	$30M—	——	——	——	——
Debt Instruments And Warrants, Fair Value Allocation, Net	$27.52M—	——	——	——	——
Debt Instruments And Warrants, Fair Value Disclosure	$31.43M—	——	——	——	——
Deferred offering costs	$711K-1.7%	$711K-5.2%	$711K-5.2%	$710.94K—	$723.13K—
Drug product manufacturing subcontractor	$344K—	$292K—	——	——	——
Financial reporting platforms	$20K—	$98K—	——	——	——
2031 and thereafter	$19.5M—	——	——	——	——
Finite-Lived Intangible Assets, Accumulated Amortization	$2.59M—	$1.56M—	——	——	——
2028	$3.98M—	——	——	——	——
2030	$3.82M—	——	——	——	——
Remainder of 2026	$3.14M—	——	——	——	——
2027	$4.18M—	——	——	——	——
2029	$3.83M—	——	——	——	——
Gross Carrying Amount	$41.03M—	——	——	——	——
Goodwill, Gross	$24.68M—	——	——	——	——
Intangible Assets, Gross (Including Goodwill)	$65.71M—	——	——	——	——
Accrued interest	$387K—	$0—	——	——	——
Additional leased area (in square feet)	——	——	——	——	——
Leased area (in square feet)	——	——	——	——	——
Lessee Operating Lease Liability Payments Due	$4.2M—	——	——	——	——
2031 and thereafter	$836K—	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	$907K—	——	$1.05M—	——	——
Increase in monthly base rent, percentage	——	——	——	——	——
Number of renewal options	——	——	——	——	——
Number of agreements related to an out-license to third party	1—	——	——	——	——
Number of commercial products actively promoted	1—	——	——	——	——
Number of approved products	3—	——	——	——	——
Number of products acquired	2—	——	——	——	——
Operating Lease Weighted Average Discount Rate Percent	$0.08—	——	——	——	——
Other accrued liabilities	$548K—	$683K—	$2.06M—	——	——
Other	$545K—	$419K—	——	——	——
Patient assistance platforms	$38K—	$75K—	——	——	——
Commercial, marketing and sales	$86K—	$818K—	——	——	——
Prepaid Insurance	$530K—	$766K—	$1.01M—	——	——
Prepaid Prescription Drug User Fee Act (PDUFA) fees	$332K—	$442K—	$543K—	——	——
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$16.17-72.3%	——	——	——	$58.48—
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	$187.36K+341%	——	$133.43K+539%	$50.91K+337%	$42.52K-66.7%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$1.54M+1,668%	$1.51M+1,631%	$1.53M+1,764%	$94.95K+15.7%	$87.05K-55.9%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	$1.54M+1,668%	——	——	——	$87.05K—
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	$11M+9,811%	——	——	——	$111K—
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$16.17-72.3%	$15.96-72.7%	$15.76-74.4%	$54.73-11.1%	$58.48+158%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	$11M+9,811%	$0—	——	——	$111K—
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$31.85-67.0%	——	$38.95-73.3%	$86.5-61.9%	$96.51+326%
Share price (in dollars per share)	$21.01—	$31—	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	$1.31M+2,944%	——	——	——	$43K—
Working capital deficit	$44.8M—	——	$24.99M—	——	——
Remainder of Fiscal Year 2024	$499K—	——	——	——	——
Remainder of Fiscal Year 2025	$3.14M—	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Pelthos Therapeutics Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Pelthos Therapeutics Inc.'s total assets?: Pelthos Therapeutics Inc. (PTHS) holds $145.4M in total assets, up 15854.9% year over year.
How much debt does Pelthos Therapeutics Inc. have?: Pelthos Therapeutics Inc. carries $29.6M in total debt against $35.1M of shareholders' equity, a debt-to-equity ratio of 0.84.
How much cash does Pelthos Therapeutics Inc. have?: Pelthos Therapeutics Inc. holds $32.0M in cash and equivalents.
Can Pelthos Therapeutics Inc. cover its short-term obligations?: Its current ratio is 2.79 — current assets exceed current liabilities.
Where does Pelthos Therapeutics Inc.'s balance sheet data come from?: Every line is extracted from Pelthos Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.